IndIcatIons and dosIng
Maraviroc (MVR) is the first antiretroviral agent belonging to the new pharmacological class of CCR5-antagonists to be approved by the US Food and Drug Administration. MVR, in combination with other antiretroviral products, is indicated for adult patients infected with only CCR5-tropic HIV-1 virus strains resistant to multiple antiretroviral agents, and in presence of demonstrated active viral replication. This drug is available in film-coated tablets containing 150 or 300 mg of MVR; the recommended dose is of 150, 300 or 600 mg (depending on coadministered antiretroviral therapy and potential drug-drug interactions) twice daily. Tropism testing is required before initiation of treatment. MVR is currently included by AIFA (Agenzia Italiana del Farmaco) in a drug efficacy and safety monitoring program.
PharmacokInetIcs
Pharmacokinetics of MVR is not influenced by gender, race or weight; age appears to influence MVR clearance, but the studied range (18-54 y) is very limited and insufficient data is available for the elderly. MVR can be taken with or without food, although a plentiful breakfast can considerably reduce its bioavailability. Dose adjustment is required in patients with renal impairment who are taking CYP3A4 inhibitors, and caution is needed in case of renal, hepatic or cardiac function problems. 
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PharmacodynamIcs
HIV-1 strains can be categorized by their co-receptor tropism, i.e. their ability to use CCR5 (CCR5-tropic), CXCR4 (CXCR4-tropic), or both (dual-tropic) human chemokine receptors as coreceptors for entry into susceptible cells. MVR is a specific, slowly reversible, noncompetitive, small-molecule CCR5-antagonist, which acts by binding to the transmembrane region of this receptor, and stabilizing a conformation not recognized by the virus, which cannot enter host CD4+ cells. Resistance to MVR can occur by HIV mutagenesis, and was seen in both in vivo and in vitro samples.
effIcacy and safety
MVR has demonstrated in vitro activity against a wide range of CCR5-tropic clinical isolates, including those resistant to the four currently existing classes of antiretroviral agents. Results of phase III clinical trials (MOTIVATE 1 and 2) demonstrate that this drug, in combination with optimized background therapy (OBT: 3-6 other antiretroviral products, excluding low-dose ritonavir), is superior to OBT alone in treatment-experienced patients infected with CCR5-tropic HIV-1, causing a significantly greater reduction in viral load and an increase in CD4+ cell count. In treatment-naïve patients, MVR formally failed to prove its non-inferiority to a standard regimen consisting of AZT/3TC + efavirenz after 48 weeks. MVR appeared relatively well tolerated, with no particular concerns; in fact, no significant increases in cardiovascular events, hepatotoxicity, infections or malignancies have been reported. Several post-marketing, ongoing studies will assess the long-term safety on immune and liver function, malignancy, cardiac events, and risks associated with changes in tropism.
economIc eValuatIons
Currently, HIV treatment in Italy is based on HAART therapies, which consists in the mix of three or more antiretroviral agents. Possible combinations are made up of 2 NRTIs + 1 NNRTI, 2 NRTIs + 1/2 PIs, or 3 NRTIs. The daily cost of this therapy ranges from 15 to 28 €/die, with a mean of 22 €/die, for a monthly cost of about 650 €. This evaluation is based on dosages reported in the SPCs (Summary of Products Characteristics) and ex-factory prices. As no alternative strategy can be identified, since MVR is to be added to standard OBT therapy, monthly pharmaceutical costs for this treatment are simply presented in Table III 
